Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment

Oncology

Volumn 79, Issue 1-2, 2010, Pages 85-92

  Wörns, Marcus Alexander ^a   Schuchmann, Marcus ^a   Düber, Christoph ^a   Otto, Gerd ^a   Galle, Peter Robert ^a   Weinmann, Arndt ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Efficacy; Hepatocellular carcinoma; Safety; Sequential therapy; Sorafenib; Sunitinib

Indexed keywords

SORAFENIB; SUNITINIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASCITES; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONFUSION; CONJUNCTIVAL HEMORRHAGE; DESQUAMATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; EPISTAXIS; ESOPHAGUS VARICES; FATIGUE; FEMALE; HUMAN; HYPERTENSION; INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; MALE; METASTASIS; NAUSEA; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; SIDE EFFECT; STOMACH DISEASE; SYNCOPE; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 78149336711     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320363     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
3. Lopez PM, Villanueva A, Llovet JM: Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535-1547.
4. Zhu AX: Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11: 790-800.
5. Worns MA, Weinmann A, Schuchmann M, Galle PR: Systemic therapies in hepatocellular carcinoma. Dig Dis 2009; 27: 175-188.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
7. Worns MA, Galle PR: Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 2009; 19: 615-629.
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors - European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
9. Raoul JL, Finn RS, Kang YK, Park JW, Harris R, Coric V, Donica M, Walters I: An openlabel phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC) (abstract). J Clin Oncol 2009; 27(suppl):4577.
10. Finn RS, Kang Y, Park JG, Harris R, Donica M, Walters I: Phase II, open label study of brivanib alaninate in patients (pts) with hepatocellular carcinoma (HCC) who failed prior antiangiogenic therapy (abstract 200). Gastrointestinal Cancers Symposium, San Francisco, 2009.
11. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
12. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
13. Rini BI: Sunitinib. Expert Opin Pharmacother 2007; 8: 2359-2369.
14. Faivre S, Demetri G, Sargent W, Raymond E: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6: 734-745.
15. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27: 3027-3035.
16. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL: Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10: 794-800.
17. Hoda D, Catherine C, Strosberg J, Valone T, Jump H, Campos T, Halina G, Wood G, Hoffe S, Garrett CR: Phase II study of sunitinib malate in adult pts (pts) with metastatic or surgically unresectable hepatocellular carcinoma (HCC) (abstract 267). Gastrointestinal Cancers Symposium, Orlando, 2008.
18. Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovacs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G: Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010; 15: 285-292.
19. Zhu AX, Duda DG, Sahani DV, Jain RK: Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J 2009; 15: 263-268.
20. Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM: Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008; 179: 81-86.
21. Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H: Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008; 54: 1373-1378.
22. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C: Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115: 61-67.
23. Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U: Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009; 76: 350-354.
24. Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J, Escudier B: Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009; 182: 29-34.
25. Merseburger AS, Simon A, Waalkes S, Kuczyk MA: Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 2009; 9: 1429-1434.
26. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
27. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300.
28. Worns MA, Weinmann A, Pfingst K, Schulte- Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Duber C, Otto G, Galle PR: Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-495.
29. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
30. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
31. Forner A, Llovet JM, Bruix J: Sunitinib and the benefits of a negative study. Lancet Oncol 2009; 10: 743-744.
32. Faivre SJ, Bouattour M, Dreyer C, Raymond E: Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J Clin Oncol 2009; 27:e248-e250; author reply e251-e252.
33. Telli ML, Witteles RM, Fisher GA, Srinivas S: Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008; 19: 1613-1618.
34. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019.
35. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
36. Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX: Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009; 14: 717-725.
37. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
38. Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, Voliotis D, Anderson S, Moscovic M, Ricci S: Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis (abstract)? J Clin Oncol 2008; 26(suppl):4518.
39. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Konigsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M: Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14: 70-76.